BIOTIE THERAPIES CORP 
By BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 2 January 2013 at 1:40 p.m
David Cook appointed Chief Financial Officer of Biotie
David Cook, (age 45), has been appointed Chief Financial Officer (CFO) of Biotie Therapies Corp., effective February 25, 2013. He will become a member of the Group's management team and will report to Timo Veromaa, President and Chief Executive Officer. David will be based at the Company's headquarters in Turku, Finland. Kristian Rantala, current interim CFO, will resume his prior duties as Vice President, Finance and Administration, Finland.
David Cook, a British native, has extensive industry expertise in life science enterprises in finance, strategy, investor relations and M&A. Previously David was CFO, International, of Jazz Pharmaceuticals, Inc., a NASDAQ listed company and before this CFO of EUSA Pharma Inc., which was acquired by Jazz Pharmaceuticals in mid-2012. Before joining EUSA David was Group Financial Controller at Zeneus Pharma Limited and prior to that worked for PricewaterhouseCoopers in the United Kingdom and Australia. David is a qualified chartered accountant and graduated from the University of Oxford with a degree in Chemistry.
Timo Veromaa, CEO of Biotie:
"I am very pleased that David is joining Biotie's management team and we look forward to his contributions to the growth of the group. As Biotie continues to mature as a company, David's extensive experience in building profitable biotech businesses will be extremely valuable."
Turku, 2 January 2013
Biotie Therapies Corp.
Timo Veromaa
President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com:
mailto:virve.nurmi@biotie.com
Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com:
http://www.biotie.com/
ABOUT BIOTIE
Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease. The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential.
Biotie's most advanced product, Selincro(TM) (nalmefene), licensed to Lundbeck A/S, has on 14 December 2012 received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorization of Selincro(TM) for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. In addition, Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant which has successfully completed a Phase 2b study in 420 patients with advanced Parkinson's disease. Biotie shares are listed on NASDAQ OMX Helsinki Ltd.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Biotie Therapies Oyj via Thomson Reuters ONE
